Our High-Affinity Probe (HAP) technology provides precise, in situ quantification of therapeutic binding sites on tumor tissues, supporting advanced drug development and personalized oncology applications. In clinical settings, HAPs offer a transformative approach to patient-specific treatment profiling, empowering oncologists to make data-driven recommendations for patients with limited therapeutic options.
By simulating and visualizing specific drug binding interactions, HAPs enable pharmaceutical and biotech companies to optimize clinical trial design, enrich trial populations and explore repurposing opportunities across various tumor types. This versatile technology is a powerful tool for advancing precision medicine and improving outcomes in cancer research and treatment.
High-Affinity Probe (HAP) technology provides a precise and versatile platform for detecting therapeutic binding sites on tumor tissues. Our probes are engineered for high specificity and sensitivity, enabling in situ quantification of binding site accessibility and density.
HAPs integrate seamlessly into various workflows, from preclinical drug development to exploratory clinical research, supporting applications such as drug-target interaction mapping, patient stratification, and therapy exploration for challenging cases. The technology enhances precision in oncology research by delivering actionable molecular insights that drive innovation across the drug development pipeline.
Our High-Affinity Probes provide an indispensable tool to accelerate drug development timelines across a wide range of therapeutics, including small molecules, radioligands, monoclonal antibodies (MABs), bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell targets.
target accessibility and binding affinity with precision
accelerate progression to clinical stages.
iteration and validation. Integrates seamlessly into standard
pathology workflows to meet diagnostic requirements.
We offer HAP-based solutions across the entire drug development lifecycle, enabling precise therapeutic binding site detection to optimize patient selection and treatment strategies. In preclinical research, our HAP-based tumor profiling helps validate target accessibility and binding site density in diverse tumor models. During clinical trials, our HAP-driven patient stratification enhances trial design by identifying patients most likely to benefit from targeted therapies, including ADCs and bispecifics. In post-marketing applications, our HAP-based real-world response assessment provides insights into drug efficacy across broader patient populations, supporting label expansion and biomarker refinement.
High-Affinity Probe (HAP) technology provides insights into drug binding site accessibility on tumor tissues, offering valuable data for physicians exploring potential treatment options for patients with limited or exhausted choices. By profiling the interaction between approved therapies and a patient's tumor at the molecular level, HAPs generate research-driven insights into potential drug matches based on tumor-specific characteristics.
While this technology is designed for research use only and is not extensively clinically validated yet, it can inform discussions between physicians and patients about personalized treatment approaches, enabling data-driven exploration of alternative therapies within a research framework.
For more information or to get started, please reach out to us at info@bav.bio or use the contact form below. Our team will respond promptly to assist with your inquiry and provide the information you need. We look forward to hearing from you.
